Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients (Record no. 76343)

MARC details
000 -LEADER
fixed length control field 02639cam a2200169 4500
001 - CONTROL NUMBER
control field NMDX7447
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2017 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Nair, S.
240 ## - UNIFORM TITLE
Uniform title <a href="International Journal of Ophthalmology">International Journal of Ophthalmology</a>
245 ## - TITLE STATEMENT
Title Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2017
500 ## - GENERAL NOTE
General note NMUH Staff Publications
500 ## - GENERAL NOTE
General note 10
520 ## - SUMMARY, ETC.
Summary, etc. &lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;AIM:&lt;span style="font-weight: normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy.&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;METHODS: &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired &lt;em&gt;t&lt;/em&gt;-test at the 5% significance level.&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;RESULTS: &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (&lt;em&gt;P&lt;/em&gt;&amp;lt;0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (&lt;em&gt;P&lt;/em&gt;&amp;lt;0.001).&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;CONCLUSION: &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&amp;nbsp;
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.ncbi.nlm.nih.gov/pubmed/28861351">https://www.ncbi.nlm.nih.gov/pubmed/28861351</a>
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554844/pdf/ijo-10-08-1251.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554844/pdf/ijo-10-08-1251.pdf</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Shelving location Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Staff publications for NMDX Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Shelves 07/06/2022   07/06/2022 07/06/2022 Book
London Health Libraries Koha Consortium privacy notice